Pediatrix Medical Group (NYSE:MD) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Pediatrix Medical Group (NYSE:MD) from a buy rating to a strong-buy rating in a research note released on Sunday,Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on the company. Jefferies Financial Group cut Pediatrix Medical Group from a “buy” rating to a “hold” rating and upped their price target for the stock from $27.00 to $28.00 in a research note on Wednesday, August 19th. UBS Group raised their price objective on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Weiss Ratings raised shares of Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 price target on shares of Pediatrix Medical Group in a research note on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $26.60.

Pediatrix Medical Group Stock Performance

Shares of MD opened at $26.81 on Friday. The company has a 50-day simple moving average of $26.42 and a two-hundred day simple moving average of $23.62. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.32 and a quick ratio of 1.32. The firm has a market capitalization of $2.18 billion, a PE ratio of 12.83 and a beta of 0.64. Pediatrix Medical Group has a one year low of $15.69 and a one year high of $27.94.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. The firm had revenue of $487.78 million for the quarter, compared to the consensus estimate of $478.49 million. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.53 EPS. On average, analysts anticipate that Pediatrix Medical Group will post 2.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Pediatrix Medical Group

Hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new position in shares of Pediatrix Medical Group during the second quarter valued at $33,000. Nykredit A S purchased a new position in shares of Pediatrix Medical Group in the 2nd quarter worth about $35,000. Transamerica Financial Advisors LLC bought a new position in Pediatrix Medical Group in the 4th quarter worth about $30,000. Eurizon Capital SGR S.p.A. bought a new position in Pediatrix Medical Group in the 4th quarter worth about $33,000. Finally, TD Private Client Wealth LLC purchased a new stake in Pediatrix Medical Group during the 4th quarter valued at about $39,000. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc is a physician-led healthcare services company that provides specialized medical care for women, infants and children. The company partners with hospitals and health systems to deliver care through physician practices, neonatal intensive care units and other hospital-based programs.

Its services include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric hospital medicine and other pediatric subspecialties. Pediatrix physicians care for patients before, during and after childbirth, as well as children requiring specialized or critical care.